Navigation Links
Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
Date:10/29/2009

Cash and cash equivalents, end of period $456,753 $632,959

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the possibility that the acquisition of Indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to p
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
2. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
4. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
5. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
6. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
7. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
8. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
9. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
10. BioMarin Acquires Huxley Pharmaceuticals, Inc.
11. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...
(Date:5/23/2013)... de mayo de 2013  Volcano Corporation (NASDAQ: ... fabricante de herramientas de precisión para terapia guiadas ... la enfermedad vascular periférica y coronaria, anunció hoy ... enosine V asodilator I ndependent ... sesión de ensayo clínico hot line late breaking ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
(Date:5/23/2013)... 2013 Susquehanna Health is ... comprehensive babysitting training course for adolescents age 11 and ... Indianapolis pediatrician Dr. Patricia Keener after a colleague’s toddler ... adult sitter who didn’t know how to provide first ... with a medical basis that aims to reduce the ...
(Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
(Date:5/23/2013)... used next generation genomic analysis to determine that some ... genetic origins, which may help in predicting cancer progression. ... Cancer Research . , "This is the first study ... adjacent Gleason patterns in the same tumor allowing us ... Cheville, M.D., Mayo Clinic pathologist and one of the ...
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New ... Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol , dedicated ... who are considering filing lawsuits. , The painkiller ... liver damage, according to a 2009 report from the ... communication,” the FDA warned consumers against using more than ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Dr. ... her new charitable organization in Orange County, OCCares , ... in Orange County. The event details are as follows: ... Orangewood Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 ... pop crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... 67-Year-Old Great-Grandmother & Geriatric Care Manager Marion Somers, PhD, Will Visit 15 ... ... Politicians, NEW YORK, Sept. 24 Leading ... today kicked off her second national bus tour this year to raise,awareness ...
... Campaign Supports Susan G. Komen for the Cure with its ... Auction this October, WHAT: Emmy Award-winning journalist and TV personality Cristina ... Project Pink Campaign. Munchkin, Inc. ... products -- is once again reminding women everywhere "Don,t Duck a ...
... YORK, Sept. 24 There is clear evidence,that ... added to U.S. water,supplies, present potential risks to ... (NRC) first-ever published review of the,fluoride/thyroid literature.(A) ... 2/3 of U.S.,public water supplies, ostensibly to reduce ...
... 2007 -- A new study reports important evidence ... diagnosed with schizophrenia. Schizophrenia is considered one ... disorders, which has three distinct facets, often referred ... reduced capacity for pleasure), and cognitive (impairments in ...
... methods significantly raise exam rate, study finds , MONDAY, ... doctors, offices can improve colorectal cancer screening rates, a ... most common kind of cancer and the third leading ... patients don,t experience any symptoms until the disease is ...
... Health Solutions, Inc.,("SXC" or the "Company") (NASDAQ: SXCI ... services, announces that Gordon S. Glenn,Chairman and Chief Executive ... Officer, will present at the 2007 UBS Global Life,Sciences ... SXC,s presentation,will take place on Tuesday, September 25, 2007 ...
Cached Medicine News:Health News:Elder Care Author Doctor Marion Launches Second National Tour to Raise Awareness About Aging & Elder Care Issues in America 2Health News:Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research 2Health News:Fluoride Damages the Thyroid, Report Shows 2Health News:Potential new approach to treat cognitive impairments in schizophrenia 2Health News:Doctors' Office Outreach Boosts Colon Cancer Screening 2